Abstract

BIOEQUIVALENCE STUDY OF TWO ORAL LINCOMYCIN-SPECTINOMYCIN COMBINATIONS (LINCO-SPECTIN 100® AND RIGHTO-SPECTIN® IN BROILER CHICKENS

Ashraf Elkomy and Mohamed Aboubakr*

ABSTRACT

The present study was designed to assess the comparative bio-equivalence of Linco-Spectin 100® and Righto-spectin® in healthy broiler chickens after oral administration of both products in a dose of 16.65 mg lincomycin hydrochloride and 33.35 mg spectinomycin sulphate/kg b.wt. Twenty four broiler chickens were divided into two groups. The first group was designed to study the pharmacokinetics of Linco-Spectin 100®, while the 2nd group was designed to study the pharmacokinetics of Righto-spectin®. Each broiler chicken in both groups was orally administered with 16.65 mg lincomycin and 33.35 mg spectinomycin /kg b.wt. Blood samples were obtained from the wing vein and collected immediately before and at 0.08, 0.16, 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours after a single oral administration. The disposition kinetics of Linco-Spectin 100® and Righto-spectin® following oral administration of 16.65 mg lincomycin and 33.35 mg spectinomycin /kg b.wt, revealed that the maximum blood concentration of lincomycin [Cmax] were 4.81 and 4.62 μg/ml and attained at [tmax] of 1.36 and 1.35 hours, respectively. Spectinomycin in both products could not be detected in blood after oral administration that make this antibiotic of choice for treatment of enteric infections caused by organisms sensitive to spectinomycin. In conclusion: Righto-spectin® is bioequivalent to Linco-Spectin 100® since the ratios of Cmax, AUC0-24 and AUC0-∞ (T/R) was 0.96, 0.92 and 0.91 respectively. These are within the bioequivalence acceptance range. Righto-spectin® and Linco-Spectin 100® are therefore bioequivalent and interchangeable.

Keywords: .